Fenfluramine low dose - Zogenix

Drug Profile

Fenfluramine low dose - Zogenix

Alternative Names: Brabafen; Fintepla; Low-dose fenfluramine; ZX-008

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Brabant Pharma
  • Developer Brabant Pharma; Zogenix
  • Class Amphetamines; Anorectics; Antiepileptic drugs; Small molecules
  • Mechanism of Action Serotonin receptor agonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome; Lennox-Gastaut syndrome
  • Preclinical Epilepsy

Most Recent Events

  • 06 Feb 2018 Fenfluramine low dose receives Breakthrough Therapy status for Dravet syndrome in USA
  • 31 Jan 2018 Efficacy data from the phase III Study 1 in Dravet syndrome released by Zogenix
  • 31 Jan 2018 Zogenix completes enrolment in the phase III Study 1504 in Dravet syndrome (Adjunctive treatment, In children, In adolescents, In adults) in USA, United Kingdom, France, Canada, Germany, Spain ad Netherlands (NCT02926898)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top